Ketogenic Diet Treatment in Diffuse Intrinsic Pontine Glioma in Children: retrospective analysis of feasibility, safety and survival data
Details
Under indefinite embargo.
UNIL restricted access
State: Public
Version: After imprimatur
License: Not specified
UNIL restricted access
State: Public
Version: After imprimatur
License: Not specified
Serval ID
serval:BIB_4654E37B9F8F
Type
A Master's thesis.
Publication sub-type
Master (thesis) (master)
Collection
Publications
Institution
Title
Ketogenic Diet Treatment in Diffuse Intrinsic Pontine Glioma in Children: retrospective analysis of feasibility, safety and survival data
Director(s)
VON BUEREN A.
Institution details
Université de Lausanne, Faculté de biologie et médecine
Publication state
Accepted
Issued date
2020
Language
english
Number of pages
27
Abstract
Background: Diffuse Intrinsic Pontine Glioma (DIPG) is one of the most devastating diseases amongst children with cancer, thus novel strategies are urgently needed. We retrospectively evaluated DIPG patients exposed to the carbohydrate restricted ketogenic diet (KD) with regards of feasibility, safety and overall survival (OS).
Methods: Searches of MEDLINE and Embase identified four hits meeting the inclusion criteria (diagnosis of DIPG and exposure to KD ≥ 3 months). One additional case was identified by contact with experts. Individual patient data were extracted from publications or obtained from investigators.
Feasibility was defined as number of patients who were able to use the KD for ≥ 3 months. OS was estimated by the Kaplan-Meier method.
Results: Five DIPG patients (males, n=3; median age 4.4 years; range, 2.5-15 years) meeting the inclusion criteria were identified. Analysis of the available data showed that the KD is generally well tolerated. Only mild gastro-intestinal complaints, one borderline hypoglycemia (2.4 mmol/l) and one hyperketosis (max 7.2 mmol/l) were observed. Further analyses showed that the KD was feasible in DIPG patients (median KD duration, 7 months; range, 0.25-2 years). The median OS was 18.7 months.
Conclusion: The KD appears to be feasible and safe, no serious adverse events were observed. The OS appeared to be favorable. These results may encourage further efforts on a larger scale; ideally through an observational prospective study assessing the most adequate nutritional composition of the KD and its impact on DIPG patients when started shortly after diagnosis.
Methods: Searches of MEDLINE and Embase identified four hits meeting the inclusion criteria (diagnosis of DIPG and exposure to KD ≥ 3 months). One additional case was identified by contact with experts. Individual patient data were extracted from publications or obtained from investigators.
Feasibility was defined as number of patients who were able to use the KD for ≥ 3 months. OS was estimated by the Kaplan-Meier method.
Results: Five DIPG patients (males, n=3; median age 4.4 years; range, 2.5-15 years) meeting the inclusion criteria were identified. Analysis of the available data showed that the KD is generally well tolerated. Only mild gastro-intestinal complaints, one borderline hypoglycemia (2.4 mmol/l) and one hyperketosis (max 7.2 mmol/l) were observed. Further analyses showed that the KD was feasible in DIPG patients (median KD duration, 7 months; range, 0.25-2 years). The median OS was 18.7 months.
Conclusion: The KD appears to be feasible and safe, no serious adverse events were observed. The OS appeared to be favorable. These results may encourage further efforts on a larger scale; ideally through an observational prospective study assessing the most adequate nutritional composition of the KD and its impact on DIPG patients when started shortly after diagnosis.
Keywords
Pediatric hematology/oncology, Nutrition, Gliomas, brainstem, Tumors, brain, Neuro-oncology, CNS tumors
Create date
07/09/2021 11:23
Last modification date
08/11/2022 6:38